Treatment of Schamberg's disease with pentoxifylline - therapeutic trial

Authors

  • Rostami Mogaddam Majid

Keywords:

Schamberg’s disease, pentoxifylline

Abstract

Thirty patients with Schamberg's disease were started on pentoxifylline (400 mg three times daily) for a period of 9 weeks. Improvement was assessed at 3 weekly intervals by two observers independently and graded as mild (<25%), moderate (25-50%) and marked (>50%). Marked improvement was observed in 15/30 (50%) patients. We conclude that pentoxifylline should be considered as first line therapy in all patients with Schamberg's disease.

References

Champion RH. Purpura. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Textbook of Dermatology, Vol III, 6th edn. London: Blackwell Scientific Publications; 1998. p. 2149-2151.

Kano Y, Hiroyama K, Shiohra T Successful treatment of Schamberg's disease with pentoxifylline. J Am Acad Dermatol 1997; 36: 827-30.

Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621.

Ely H. Is pentoxifylline the drug of the decade? J Am Acad Dermatol 1994; 30: 603-40.

Schwarz A, Arragne Y, Simson M et al. Pentoxifylline suppresses UVB induced cutokine release by keratinocytes (abstract). J Invest Dermatol 1993; 101: 388.

Downloads

Published

2016-12-24

How to Cite

1.
Majid RM. Treatment of Schamberg’s disease with pentoxifylline - therapeutic trial. J Pak Assoc Dermatol [Internet]. 2016Dec.24 [cited 2025Apr.18];18(2):97-9. Available from: https://jpad.com.pk/index.php/jpad/article/view/574

Issue

Vol. 18 No. 2 (2008): April - June

Section

Original Articles